calendardigital-marketingit-solutionslocation-dotlogo-footertech-journal-logo-footerweb-development

Open filters Close filters

BTLJ Blog
March 19th, 2012
Under the recently passed Leahy-Smith America Invents Act (“AIA”), generic drug manufacturers will be able to use post grant review (“PGR”) to effectively invalidate or constrain pharmaceutical patents. The efficiency of PGR and the lower burden of proof for the PGR process in comparison to patent litigation makes PGR an attractive new tool for generic drug manufacturers. Furthermore, ...